劲方医药-B今日盘中大涨5.48%，引起了市场的广泛关注。
消息面上，公司近日宣布其自主研发的口服高选择性KRAS G12D抑制剂GFH375被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟用于单药治疗至少接受过一种系统性治疗的KRAS G12D突变型转移性患者，系国内首个获该适应症BTD认定的KRAS G12D抑制剂单药治疗方案。
KRAS突变在胰腺癌中发生率高达90%，而该癌种五年生存率低于10%，临床需求迫切。公司计划于今年学术会议中公布GFH375在不同适应症试验中的最新数据，市场对该管线商业化前景的关注持续升温。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.